New Report: Cayman Islands Enhances Global Innovation and Economic Development Without Tax Harm
13.10.2021 10:00:00 EEST | Business Wire | Press release
Cayman Finance today is releasing “Cayman: Engine of Growth and Good Governance,” a new report that documents how the jurisdiction’s unique combination of tax neutrality, high-quality legal and regulatory system, and professional expertise attract Collective Investment Vehicles (CIVs) and Multinational Enterprises (MNEs), providing economic benefits to other jurisdictions without posing tax harm.
Trade and investment are engines of innovation and growth. Underpinning both are effective institutions: good governance (especially, political stability and the rule of law), a high-quality legal system that protects owners of assets, and effective and adaptive legislation and regulation. This new report has been commissioned by Cayman Finance to help clarify how the Cayman Islands has successfully combined all of these attributes with others that make it unique to international investors, to help drive the international economy and facilitate global economic growth.
“This report documents how the Cayman Islands’ pure tax neutrality and commitment to good governance enable investors to pool capital securely and transparently and pursue investment opportunities that drive economic growth, create jobs and generate tax revenue in countries around the world,” said Jude Scott, the CEO of Cayman Finance. “As this research shows, Cayman also poses no tax harm to other jurisdictions due to its tax neutral regime and early adoption of tax information exchange agreements, Common Reporting Standards (CRS), and other elements of the OECD’s Base Erosion and Profit Shifting (BEPS) project.”
Cayman’s approach has a competitive advantage. While some jurisdictions offer some similar attributes, a key reason that both collective investment vehicles (CIVs) and multinational enterprises (MNEs) choose to domicile entities in Cayman rather than elsewhere is that Cayman offers true tax neutrality at minimal cost. By contrast, many other jurisdictions are at best able only to facilitate a facsimile of tax neutrality through the use of special structures and double taxation treaties; moreover, these special structures are highly limiting and come with additional costs.
“Cayman: Engine of Growth and Good Governance” combines a detailed review of scholarly research and publications from the EU, OECD, IMF, FATF, UNCTAD, and other national and international bodies. Key findings include:
- CIVs and MNEs choose to domicile entities in Cayman rather than in other jurisdictions because Cayman offers pure tax neutrality at minimal cost in a well-regulated legal environment.
- Cayman and other tax neutral financial centres benefit developed jurisdictions like the EU as well as less developed countries by facilitating the provision of trillions of dollars of funding to infrastructure and other projects, increasing economic activity and innovation.
- Cayman’s pure tax neutrality enables entities to avoid double and triple taxation, facilitating greater levels of economic activity in the EU and elsewhere than would otherwise be the case. Due to Cayman’s commitment to information sharing, this activity is transparently reported to tax authorities in EU member states and other jurisdictions and leads to increased government revenue through a wide range of taxes.
“Tax neutrality is not tax avoidance. A tax neutral jurisdiction does not add an extra layer of tax on top of what investors and companies owe in their own jurisdictions in compliance with their domestic tax rules. This report demonstrates that as part of the international financial system Cayman is a transparent and globally responsible partner that improves access to capital in the US, UK, EU and other developed and developing countries,” said Mr Scott. “Moreover, it shows that International standards-setting and policy-making efforts should recognise and support the beneficial contributions to economic growth CIVs and MNEs domiciled in Cayman make globally.”
A “Cayman: Engine of Growth and Good Governance” was authored by leading economist Julian Morris and is available, along with other Cayman Finance reports, at www.caymanfinance.ky.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005314/en/
Contact information
Travis Webster
enquiries@caymanfinance.ky
+1 (345) 769-6200
@CaymanFinance
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
